VBL's psoriasis drug candidate meets primary goals in Phase II trial

03/19/2012 | Business Wire

VBL Therapeutics' drug candidate VB-201 significantly reduced vascular inflammation linked to atherosclerotic lesions in patients with severe psoriasis 12 weeks after receiving the treatment, according to a Phase II sub-trial that involved the use of PET/CT scans to assess inflammation. The results were presented at a meeting in San Diego.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations